Tonsil T cell immunity to human papillomavirus in the absence of detectable virus in healthy adults

Laryngoscope

Volumn 118, Issue 3, 2008, Pages 459-463

  Hobbs, Christopher G L ^a,b   Groves, Eleanor ^b   Davenport, Victoria ^b   Bailey, Michael ^b   Williams, Neil A ^b   Birchall, Martin A ^b   Heyderman, Robert S ^c  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Human papillomavirus; T cell immunity; Tonsil

Indexed keywords

CD45RO ANTIGEN; RECOMBINANT ANTIGEN; VIRUS ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; HYBRIDIZATION; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY CELL; MUCOSAL IMMUNITY; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TONSIL; TONSILLECTOMY; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS RECOMBINANT; WART VIRUS; ADOLESCENT; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; T LYMPHOCYTE;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 6; HUMANS; MALE; MIDDLE AGED; T-LYMPHOCYTES; TONSIL;

EID: 42449146177     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e31815aedb3     Document Type: Article

References (25)

1. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005;32(Suppl 1):S16-S24.
2. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-475.
3. Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birchall MA, Thomas SJ. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 2006;31:259-266.
4. Rintala MA, Grenman SE, Jarvenkyla ME, Syrjanen KJ, Syrjanen SM. High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study. Clin Infect Dis 2005;41:1728-1733.
5. Rees LE, Jones PH, Ayoub O, et al. Smoking influences the immunological architecture of the human larynx. Clin Immunol 2006;118:342-347.
6. Cox BD. Health and Lifestyle Survey. Cambridge, U.K.: The Health Promotion Trust; 1987.
7. Johnson AM, Mercer CH, Erens B, et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet 2001;358:1835-1842.
8. Davenport V, Guthrie T, Findlow J, Borrow R, Williams NA, Heyderman RS. Evidence for naturally acquired T cell-mediated mucosal immunity to Neisseria meningitidis. J Immunol 2003;171:4263-4270.
9. Guthrie T, Hobbs CG, Davenport V, Horton RE, Heyderman RS, Williams NA. Parenteral influenza vaccination influences mucosal and systemic T cell-mediated immunity in healthy adults. J Infect Dis 2004;190:1927-1935.
10. Williams NA, Hill TJ, Hooper DC. Murine epidermal antigen-presenting cells in primary and secondary T-cell proliferative responses to a soluble protein antigen in vitro. Immunology 1990;71:411-416.
11. Plebanski M, Saunders M, Burtles SS, Crowe S, Hooper DC. Primary and secondary human in vitro T-cell responses to soluble antigens are mediated by subsets bearing different CD45 isoforms. Immunology 1992;75:86-91.
12. Lacey CJ, Thompson HS, Monteiro EF, et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TAGW, in persons with genital warts. J Infect Dis 1999;179:612- 618.
13. de Jong A, O'Neill T, Khan AY, et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 2002;20:3456-3464.
14. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-361.
15. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998;36:3020-3027.
16. Cheng WF, Lee CN, Su YN, et al. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus- infected populations. Immunology 2005;115:136-149.
17. Williams OM, Hart KW, Wang EC, Gelder CM. Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types. J Virol 2002;76:7418-7429.
18. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003;14-19.
19. Watanabe S, Ogura H, Fukushima K, Yabe Y. Comparison of Virapap filter hybridization with polymerase chain reaction and southern blot hybridization methods for detection of human papillomavirus in tonsillar and pharyngeal cancers. Eur Arch Otorhinolaryngol 1993;250:115-119.
20. Klussmann JP, Weissenborn SJ, Wieland U, et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001;92:2875-2884.
21. Gelder CM, Williams OM, Hart KW, et al. HLA class II polymorphisms and susceptibility to recurrent respiratory papillomatosis. J Virol 2003;77:1927-1939.
22. Pinto LA, Edwards J, Castle PE, et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 2003;188:327-338.
23. Pinto LA, Viscidi R, Harro CD, et al. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 2006;353:451-462.
24. Liu XS, Abdul-Jabbar I, Qi YM, Frazer IH, Zhou J. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology 1998;252:39-45.
25. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-1765.